TABLE 2.
Phenotypic or genotypic acquired resistance in patients of poor outcomes
| Patient no. | Acquired phenotypic drug resistancea | Acquired genotypic drug resistancea | Genetic drug resistance consistent with phenotypeb | Other mutations in drug resistance related genesb |
|---|---|---|---|---|
| 1 | / | / | / | / |
| 2 | PZA | PZA | pncA_L85R*, pncA_166c_in* | / |
| 3 | MFX2.0, SLID | FQ, SLID | gyrA A90V→D94N, rrs_a1401g | / |
| 4 | PTO | / | / | / |
| 5 | SLID | SLID | rrs_a1401g | ethA S57P*, ethA Y461stop* |
| 7 | / | / | / | ethA S183R*, ethA Q254P*, ethA Y286stop* |
| 8 | EMB, PTO, CS | EMB, PTO, CS | embB M306V; ethA_W116C*; alr_c-13g,L113R,Y388D* | gyrB T500A; pncA D8A*, pncA T142S* |
| 9 | MFX2.0 | FQ | gyrB_E501D* | |
| 10 | MFX2.0 | FQ | gyrA_A90V→D94G | / |
| 11 | SLID | SLID | rrs_a1401g* | / |
| 12 | / | / | / | / |
| 13 | FQ, PZA | FQ, PZA | gyrA_D94Y, pncA_T153P | / |
| 14 | SLID, CS | SLID | rrs_a1401g | / |
| 15 | / | / | / | / |
| 17 | FQ, PTO | FQ, PTO | gyrA_D94N; ethA_F48V*, ethA_694tc_in* | / |
| 18 | SLID | SLID | rrs_a1401g | / |
| 19 | MFX2.0 | FQ | gyrB_A504V* | / |
| 20 | / | EMB, FQ | / | embB_Q497H, gyrB_D461N |
a
Boldface type indicates the genetic mutation responsible for resistance was not found. SLID, second-line injectable drug; FQ, fluoroquinolone; EMB, ethambutol; PZA, pyrazinamide; LFX, levofloxacin; MFX, moxifloxacin; PTO, prothionamide; CS, cycloserine; /, not applicable.
b
*, hetero-resistance.